

13 January 2025

ASX Announcement

Successful Nasodine Patent Defense in Singapore

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has successfully removed a competitor product to Nasodine® Nasal Spray (**Nasodine**) from the market in Singapore for infringement of Firebrick's core patent that covers the use of Nasodine as a treatment and preventative for the common cold.

Recently, Firebrick became aware of a company in Singapore, Medzolution Pte (Medzolution), that was offering for sale online a nasal spray containing povidone iodine (PVP-I), which is called 'Arrezt Antiseptic Nasal Oral Spray' (Arrezt).

In Firebrick's view and that of its patent attorneys, the promotion and sale of this nasal spray was a clear infringement of Firebrick's Singapore patent covering the use of a PVP-I nasal spray as a treatment or preventative for the common cold [Singapore Patent Application No.10201900559V titled: "Treatment and Prevention of the Common Cold using Povidone-Iodine" (the "Patent")].

The Company has now received a signed undertaking from Medzolution that:

- (a) Medzolution acknowledges the validity of Firebrick's patent;
- (b) Medzolution will immediately withdraw Arrezt from the market and cease and desist from all marketing and advertising of the product in Singapore;
- (c) Medzolution would provide full details of all stock of Arrezt in its possession and deliver that stock to Firebrick's legal representatives in Singapore;
- (d) Medzolution shall not, for as long as the Patent remains valid and in force, do any acts in Singapore that are restricted by the Patent without Firebrick's consent;

In addition, the undertaking provides legal remedies in the event that Medzolution breaches any of the terms of the undertaking, including that Medzolution consents to an injunction against its actions and that it will indemnify Firebrick against any legal costs involved in Firebrick's enforcing the undertaking.

"This is our first patent defence and a clear demonstration of the importance and strength of Firebrick's patents," said Firebrick Executive Chairman, Dr Peter Molloy. "It is also timely as we are in the process of launching into Singapore retail pharmacy through our exclusive arrangement with the Guardian pharmacy group; it is important for pharmacists and doctors to know that Nasodine is an innovative and patent-protected product that they can confidently support."

The Nasodine common cold patent is granted in 28 countries and was granted in Singapore in 2022 (announcement 25 October 2022) and expires 6 July 2035. The granted patent claims cover not only the use of intranasal PVP-I as a treatment for the common cold, but also as a

method for reducing intranasal viral load, reducing the risk of viral transmission from someone with a cold, and protecting people from cold viruses shed by others.

“While directed at treatment of the common cold, the patent provides broad protection for Nasodine that is commercially highly relevant to its positioning in Singapore as a nasal antiseptic,” added Dr Molloy.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick recently introduced Nasodine in the United States and Singapore.

Media enquiries:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com